<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01881633</url>
  </required_header>
  <id_info>
    <org_study_id>ISU-002</org_study_id>
    <nct_id>NCT01881633</nct_id>
  </id_info>
  <brief_title>A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Evaluate the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ISU Abxis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ISU Abxis Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of&#xD;
      single dosing study with three ascending dose cohorts of ISU302 in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>From Screening to Day 5 post-dose</time_frame>
    <description>Evaluation for safety data by treatment group/ Confirmative evaluation for serious adverse drug reaction/ Descriptive statistics (arithmetic mean and standard deviation) for quantitative analysis and evaluation of change from baseline/ Frequency counts for qualitative categorization of safety data&#xD;
Parameters:&#xD;
Adverse events including subjective/objective symptoms&#xD;
Physical examination&#xD;
12-lead ECG&#xD;
Vital signs&#xD;
Local tolerability test&#xD;
Clinical laboratory test: Hematology, Coagulation, Blood Chemistry, Urinalysis&#xD;
Immunogenicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Day1</time_frame>
    <description>Pharmacokinetic Parameter assessment using non-compartmental analysis from the concentration-time data/ Summary of Pharmacokinetic parameters by treatment group using descriptive statistics/ Dose proportionality&#xD;
Parameters: Cmax, AUCt, AUCinf, Tmax, t1/2, Clearance, Vd, MRTr</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>ISU302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 U/kg I.V. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISU302 30 U/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug ISU302 I.V. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISU302 60 U/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug ISU302 I.V. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ISU302 Placebo I.V. injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISU302</intervention_name>
    <arm_group_label>ISU302</arm_group_label>
    <arm_group_label>ISU302 30 U/kg</arm_group_label>
    <arm_group_label>ISU302 60 U/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male volunteers, aged between ≥ 20 and ≤ 45 years old&#xD;
&#xD;
          -  Weight ≥ 50, with calculated body mass index of 17 and 25 kg/m2&#xD;
&#xD;
               -  BMI = (Weight [kg])/(height [m])2&#xD;
&#xD;
          -  Subject is informed of the investigational nature of this study and voluntarily agrees&#xD;
             to participate in this study and comply with the relevant instructions in written&#xD;
&#xD;
          -  Considered ineligible through screening test (such as medical history, physical&#xD;
             examination, ECG, safety laboratory test) performed within 35 days prior to study&#xD;
             start (dosing of investigational products)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With symptoms indicating acute diseases within 28 days prior to start of study (dosing&#xD;
             of investigational product)&#xD;
&#xD;
          -  History or presence of clinically significant and active cardiovascular, respiratory,&#xD;
             renal, endocrine, hematological, gastrointestinal, central nervous system, psychiatric&#xD;
             disorder, autoimmune disease, or malignant tumor&#xD;
&#xD;
          -  Any medical history that may affect drug absorption, distribution, metabolism and&#xD;
             excretion(e.g., inflammatory gastric disease, gastric or intestinal ulcer, hepatic or&#xD;
             renal disease)&#xD;
&#xD;
          -  With presence of clinically significant allergic disease (including mild allergic&#xD;
             rhinitis or allergic dermatitis which does not need medication)&#xD;
&#xD;
          -  With presence of clinically significant hypersensitivity to any drugs&#xD;
&#xD;
          -  With hemolytic anemia, anemia due to blood loss (Hb &lt; 14g/dL and Hct &lt;42%)&#xD;
&#xD;
          -  With the results of safety laboratory test&#xD;
&#xD;
               1. AST (Aspartate Transaminase) or ALT (Alanine Transaminase) &gt; 1.5 times of upper&#xD;
                  normal limit&#xD;
&#xD;
               2. Total bilirubin &gt; 1.5 times of upper normal limit&#xD;
&#xD;
          -  Subject who has immune deficiency or medication with immune suppressants&#xD;
&#xD;
          -  Participation in other clinical study within 60 days prior to start of study (dosing&#xD;
             of investigational products)&#xD;
&#xD;
          -  Use of any drugs, possibly affecting drug metabolizing enzymes, within 1 month prior&#xD;
             dosing, or any drugs, possibly affecting the results of clinical trial within 10 days&#xD;
             or use of drug was not passes 5 x half-life of drug&#xD;
&#xD;
          -  Donated whole blood within 60 days, or transfused within 20 days before the study&#xD;
&#xD;
          -  History of alcohol abuse (&gt; 14 units/week) and the subject could not stop drinking&#xD;
             alcohol beverage during study period&#xD;
&#xD;
          -  Heavy smoker (&gt;10 cigarettes/day) or the subject could not stop smoking during study&#xD;
             period&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol&#xD;
&#xD;
          -  Positive in pregnancy test in urine and unwilling to follow contraception during study&#xD;
             period and following 3 months (for female subjects).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>June 14, 2013</study_first_submitted>
  <study_first_submitted_qc>June 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gaucher disease, imiglucerase, ISU302</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

